Hence, we launched a multicentre retrospective study to compare the efficacy and safety of atezolizumab in combination with carboplatin and nab-paclitaxel regimen versus carboplatin and nab-paclitaxel regimen as front-line management for treatment-naïve stage IV nonsquamous PD-L1-positive NSCLC in selected populations of Chinese patients. Here, CD274 is linked to non-small cell lung carcinoma.